marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q4
added 11-07-2022
Allscripts Healthcare Solutions Balance Sheet 2011-2024 | MDRX
Annual Balance Sheet Allscripts Healthcare Solutions
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
181 M | 948 K | 786 M | 493 M | 1.41 B | 1.22 B | 508 M | 523 M | 499 M | 338 M | 210 M |
Long Term Debt |
350 M | 168 M | 551 M | 648 M | 1.53 B | 1.29 B | 612 M | 549 M | 545 M | 363 M | 323 M |
Long Term Debt Current |
19.6 M | 22.3 M | 23.1 M | 20.1 M | 27.7 M | 15.2 M | - | - | - | 78.8 M | 44.7 M |
Total Non Current Liabilities |
- | 317 M | 710 M | 803 M | 2.2 B | 1.89 B | 750 M | 703 M | 784 M | 547 M | 530 M |
Total Current Liabilities |
547 M | 935 M | 1.21 B | 798 M | 868 M | 667 M | 513 M | 521 M | 517 M | 553 M | 497 M |
Total Liabilities |
1.02 B | 1.25 B | 1.92 B | 1.6 B | 3.07 B | 2.56 B | 1.26 B | 1.22 B | 1.3 B | 1.1 B | 1.04 B |
Deferred Revenue |
326 M | 335 M | 380 M | 467 M | 547 M | 364 M | 316 M | 293 M | 251 M | 291 M | 289 M |
Retained Earnings |
768 M | 633 M | -49.3 M | 133 M | -338 M | -187 M | -190 M | -188 M | -122 M | -17.5 M | -16.4 M |
Total Assets |
2.43 B | 2.92 B | 3.21 B | 3.18 B | 4.23 B | 3.83 B | 2.68 B | 2.51 B | 2.62 B | 2.38 B | 2.52 B |
Cash and Cash Equivalents |
188 M | 531 M | 130 M | 174 M | 156 M | 96.6 M | 117 M | 53.2 M | 63 M | 104 M | 158 M |
Book Value |
1.41 B | 1.67 B | 1.29 B | 1.58 B | 1.16 B | 1.27 B | 1.42 B | 1.28 B | 1.32 B | 1.28 B | 1.48 B |
Total Shareholders Equity |
1.41 B | 1.67 B | 1.29 B | 1.55 B | 1.12 B | 1.23 B | 1.41 B | 1.28 B | 1.32 B | 1.28 B | 1.48 B |
All numbers in USD currency
Quarterly Balance Sheet Allscripts Healthcare Solutions
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
26.4 M | 200 M | 200 M | 377 M | 350 M | 373 M | 421 M | 169 M | 168 M | 168 M | 168 M | 168 M | 551 M | 551 M | 551 M | 551 M | 648 M | 648 M | 648 M | 648 M | 907 M | 907 M | 907 M | 907 M | 718 M | 718 M | 718 M | 718 M | 612 M | 612 M | 612 M | 612 M | 539 M | 539 M | 539 M | 549 M | 545 M | 545 M | 545 M | 545 M | 363 M | 363 M | 363 M | 363 M | 323 M | 323 M | 323 M | 323 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 514 M | 518 M | 1.08 B | 1.02 B | 1.07 B | 1.15 B | 1.19 B | 1.25 B | 1.25 B | 1.25 B | 1.25 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 2.64 B | 2.64 B | 2.64 B | 2.64 B | 2.17 B | 2.17 B | 2.17 B | 2.17 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 1.18 B | 1.21 B | 1.21 B | 1.22 B | 1.3 B | 1.3 B | 1.3 B | 1.3 B | 1.07 B | 1.09 B | 1.1 B | 1.1 B | 1.03 B | 1.04 B | 1.04 B | 1.04 B |
Deferred Revenue |
- | 98.9 M | 84.9 M | 106 M | 121 M | 338 M | 364 M | 380 M | 335 M | 335 M | 335 M | 335 M | 336 M | 380 M | 380 M | 380 M | 467 M | 507 M | 531 M | 540 M | 479 M | 547 M | 547 M | 547 M | 364 M | 364 M | 364 M | 364 M | 316 M | 316 M | 316 M | 316 M | 293 M | 293 M | 293 M | 293 M | 251 M | 251 M | 251 M | 251 M | 256 M | 283 M | 291 M | 291 M | 289 M | 289 M | 289 M | 289 M |
Retained Earnings |
- | 753 M | 739 M | 803 M | 768 M | 680 M | 664 M | 642 M | 633 M | 633 M | 633 M | 633 M | -49.3 M | -49.3 M | -49.3 M | -49.3 M | 133 M | 133 M | 133 M | 133 M | -338 M | -338 M | -338 M | -338 M | -187 M | -187 M | -187 M | -187 M | -190 M | -190 M | -190 M | -190 M | -188 M | -188 M | -188 M | -188 M | -122 M | -122 M | -122 M | -122 M | -17.5 M | -17.5 M | -17.5 M | -17.5 M | -16.4 M | -16.4 M | -16.4 M | -16.4 M |
Total Assets |
- | 1.69 B | 1.71 B | 2.43 B | 2.43 B | 2.48 B | 2.54 B | 2.87 B | 2.92 B | 2.92 B | 2.92 B | 2.92 B | 3.21 B | 3.21 B | 3.21 B | 3.21 B | 3.18 B | 3.18 B | 3.18 B | 3.18 B | 4.23 B | 4.23 B | 4.23 B | 4.23 B | 3.83 B | 3.83 B | 3.83 B | 3.83 B | 2.68 B | 2.68 B | 2.68 B | 2.68 B | 2.46 B | 2.5 B | 2.5 B | 2.51 B | 2.62 B | 2.62 B | 2.62 B | 2.62 B | 2.35 B | 2.38 B | 2.38 B | 2.38 B | 2.5 B | 2.52 B | 2.52 B | 2.52 B |
Cash and Cash Equivalents |
- | 493 M | 500 M | 82.8 M | 133 M | 142 M | 160 M | 454 M | 531 M | 531 M | 531 M | 531 M | 130 M | 130 M | 130 M | 130 M | 174 M | 174 M | 174 M | 174 M | 119 M | 156 M | 156 M | 156 M | 95.6 M | 95.6 M | 95.6 M | 96.6 M | 117 M | 117 M | 117 M | 117 M | 53.2 M | 53.2 M | 53.2 M | 53.2 M | 63 M | 63 M | 63 M | 63 M | 104 M | 104 M | 104 M | 104 M | 158 M | 158 M | 158 M | 158 M |
Book Value |
- | 1.18 B | 1.2 B | 1.35 B | 1.41 B | 1.42 B | 1.39 B | 1.68 B | 1.67 B | 1.67 B | 1.67 B | 1.67 B | 1.29 B | 1.29 B | 1.29 B | 1.29 B | 1.58 B | 1.58 B | 1.58 B | 1.58 B | 1.59 B | 1.59 B | 1.59 B | 1.59 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 1.42 B | 1.42 B | 1.42 B | 1.42 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B |
Total Shareholders Equity |
- | 1.18 B | 1.2 B | 1.35 B | 1.41 B | 1.42 B | 1.39 B | 1.68 B | 1.67 B | 1.67 B | 1.67 B | 1.67 B | 1.29 B | 1.29 B | 1.29 B | 1.29 B | 1.55 B | 1.55 B | 1.55 B | 1.55 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 1.41 B | 1.41 B | 1.41 B | 1.41 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B |
All numbers in USD currency